Evaluation of the safety, immunogenicity and efficacy of a new live-attenuated lumpy skin disease vaccine in India

Lumpy skin disease (LSD) was reported for the first time in India in 2019 and since then, it has become endemic. Since a homologous (LSD-virus based) vaccine was not available in the country, goatpox virus (GPV)-based heterologous vaccine was authorized for mass immunization to induce protection aga...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Naveen Kumar, Sanjay Barua, Ram Kumar, Nitin Khandelwal, Amit Kumar, Assim Verma, Lokender Singh, Bhagraj Godara, Yogesh Chander, Garvit Kumar, Thachamvally Riyesh, Deepak Kumar Sharma, Anubha Pathak, Sanjay Kumar, Ramesh Kumar Dedar, Vishal Mehta, Mitesh Gaur, Bhupendra Bhardwaj, Vithilesh Vyas, Sarjeet Chaudhary, Vijaypal Yadav, Adrish Bhati, Rakesh Kaul, Arif Bashir, Anjum Andrabi, Raja Wasim Yousuf, Abhimanyu Koul, Subhash Kachhawaha, Amol Gurav, Siddharth Gautam, Hari Audh Tiwari, Vijay Kumar Munjal, Madhurendu K. Gupta, Rajender Kumar, Baldev R. Gulati, Jyoti Misri, Ashok Kumar, Ashok Kumar Mohanty, Sukdeb Nandi, Karam Pal Singh, Yash Pal, Triveni Dutt, Bhupendra N. Tripathi
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2023-12-01
Edice:	Virulence
Témata:	Lumpy skin disease LSD/Ranchi India homologous live-attenuated LSD vaccine
On-line přístup:	https://www.tandfonline.com/doi/10.1080/21505594.2023.2190647
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!